African and European Regulators Issue Joint Guidelines to Accelerate Ebola Vaccine Development

The African Medicines Agency (AMA) and the European Medicines Agency (EMA) have released joint guidelines aimed at speeding up the development and clinical testing of vaccines for the Bundibugyo virus (BDBV), a cause of Ebola disease. This initiative comes amidst a public health emergency in the Democratic Republic of the Congo (DRC), with cases also reported in Uganda, Kenya, and Nigeria. The guidelines emphasize fast-tracking clinical trials while upholding strict scientific standards and protecting participants, particularly vulnerable populations.